The company Tempus is seeking FDA clearance for its technology and listed on the NASDAQ stock exchange.

The entities involved

• Tempus →

  biotechnology company based in Chicago, Illinois

  • Tempus is scheduled to participate in a conference in New York City on September 4, 2025.Sun 01:41
  • Tempus AI, led by Eric Lefkofsky, is acquiring Paige to enhance its digital pathology datasets.Sat 00:42
• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• Nasdaq →

  American fully electronic stock exchange

  • Apple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Mon 17:22
  • Vanguard Short-Term Inflation-Protected Securities ETF is disclosing its holdings to the SEC and trading on the Nasdaq electronic stock exchange.Mon 16:28

Related events

• Tempus listed on Nasdaq, filed disclosures with the SEC, and received research reports from Jefferies Financial Group.Jul 31
• Teva's acquired product is currently undergoing review by the FDA.Aug 28
• Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.Sep 22
• Tetra Tech was listed on the electronic stock exchange on August 25, 2026.Aug 25
• Teva Pharmaceutical Industries Ltd. submitted an NDA for ecopipam to the FDA.Jun 18